CG Oncology, Inc. $CGON Shares Sold by NEOS Investment Management LLC

NEOS Investment Management LLC lessened its holdings in shares of CG Oncology, Inc. (NASDAQ:CGON) by 34.4% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 30,225 shares of the company’s stock after selling 15,856 shares during the quarter. NEOS Investment Management LLC’s holdings in CG Oncology were worth $1,217,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of CGON. PNC Financial Services Group Inc. grew its stake in CG Oncology by 15.2% during the second quarter. PNC Financial Services Group Inc. now owns 3,279 shares of the company’s stock worth $85,000 after buying an additional 433 shares during the period. CWM LLC boosted its position in CG Oncology by 10.9% during the 3rd quarter. CWM LLC now owns 6,865 shares of the company’s stock worth $277,000 after purchasing an additional 672 shares during the period. Strengthening Families & Communities LLC acquired a new stake in CG Oncology in the 3rd quarter valued at $40,000. Police & Firemen s Retirement System of New Jersey raised its position in CG Oncology by 10.6% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 12,879 shares of the company’s stock valued at $335,000 after purchasing an additional 1,232 shares during the period. Finally, Winthrop Capital Management LLC purchased a new position in CG Oncology in the second quarter valued at about $38,000. Hedge funds and other institutional investors own 26.56% of the company’s stock.

CG Oncology Trading Up 2.1%

CGON stock opened at $57.63 on Friday. The firm has a 50 day simple moving average of $48.49 and a 200-day simple moving average of $40.95. The company has a market capitalization of $4.65 billion, a P/E ratio of -28.25 and a beta of 1.32. CG Oncology, Inc. has a twelve month low of $14.80 and a twelve month high of $58.25.

Analyst Ratings Changes

CGON has been the topic of several analyst reports. Morgan Stanley set a $93.00 target price on CG Oncology in a report on Friday, January 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CG Oncology in a research report on Wednesday, January 21st. Piper Sandler boosted their target price on shares of CG Oncology from $55.00 to $70.00 and gave the stock an “overweight” rating in a research report on Friday, January 16th. Truist Financial upped their target price on shares of CG Oncology from $66.00 to $75.00 and gave the company a “buy” rating in a research note on Tuesday, February 10th. Finally, Royal Bank Of Canada lifted their price target on shares of CG Oncology from $61.00 to $73.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 21st. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, CG Oncology currently has a consensus rating of “Moderate Buy” and a consensus price target of $68.58.

Insiders Place Their Bets

In other news, Director James Mulay sold 11,145 shares of the business’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $52.47, for a total value of $584,778.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 7.40% of the stock is currently owned by corporate insiders.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.